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The use of nanoparticles as carriers for the delivery of therapeutic materials to target tissues has became popular in recent years and
has demonstrated great potentials for the treatments of a wide range of diseases. In this review, we summarize the advantages of nano-
technology as a common gene delivery strategy with emphasis on ocular therapy. Particular attention is paid to the CK30-PEG com-
pacted DNA nanoparticles that have been successfully tested in the eye, lung, and brain. These particles resulted in higher
transfection eﬃciency and longer duration of expression than other non-viral vectors without any toxicity or other side eﬀects. They have
been safely used clinically and are eﬃcient for a broad range of gene therapy applications. The review also discusses mechanisms of nano-
particle uptake and internalization by cells, obstacles and limitations to the use of this technology, as well as novel methodologies to
optimize nanoparticle driven gene expression.
Published by Elsevier Ltd.
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range of medical research ﬁelds has become a popular
strategy in recent years. These particles can serve as carriers
for drugs, peptides, vaccines and oligonucleotides and have
been successfully delivered to multiple targets including
cancerous cells and other diseased tissues. Nanoparticles
also have great potential as a strategy for gene therapy
and can be used to treat genetic defects in vitro and in vivo.
Historically, viral vectors have been the preferred mech-
anism for transfer of nucleic acids into tissues of interest,
and they have dominated the ﬁeld for some time (Kay,
Glorioso, & Naldini, 2001). In a phase I/II clinical trial
using a recombinant adeno-associated viral vector (rAAV)
containing the herpes-simplex-virus thymidine kinase gene
to treat hormone-refractory prostate cancer, two patients
(out of six) responded positively to the therapy (Shirakawa
et al., 2007).
The ﬁeld of viral gene therapy in the retina has seen var-
ious successes. In a successful scenario, rAAV was used to
transfer RPE65 cDNA to the RPE65-deﬁcient eyes of Bri-0042-6989/$ - see front matter Published by Elsevier Ltd.
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led to the partial rescue of retinal function as demonstrated
by electrophysiology and behavioral assessments. Further-
more, this restoration was stable for longer than three years
without adverse eﬀects (Acland et al., 2001, 2005). Another
example of a successful viral gene therapy treatment comes
from a phase I clinical trial using AAV to deliver pigment
epithelium-derived factor (PEDF) to the eyes of patients
diagnosed with age-related macular degeneration (AMD)
and showed a signiﬁcant level of reduction in neoangiogen-
esis associated with disease progression (Campochiaro
et al., 2006).
Interestingly, in spite of the fact that many retinal
degenerative diseases are associated with a single mutation
in phototransduction genes, there have been few positive
reports for gene therapy-mediated rescue of such pheno-
types. Modiﬁed HIV vectors have been used to preserve
some retinal function in two recessive retinitis pigmentosa
models: the Royal College of Surgeons rat (which carries
a mutation in Mertk) and the retinal degeneration (rd)
mouse (which carries a mutation in the beta subunit of
cGMP phosphodiesterase) (Takahashi, Miyoshi, Verma,
& Gage, 1999; Tschernutter et al., 2005). Research on dom-
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(Gorbatyuk, Justilien, Liu, Hauswirth, & Lewin, 2007;
Lewin et al., 1998) or RNAi mediated knockdown (Cash-
man, Binkley, & Kumar-Singh, 2005) of the mutant pro-
teins; such studies have reported moderate improvement
on the disease phenotype. One of the exciting possibilities
with RNAi involves non-mutation dependent knockdown,
i.e. knockdown of all native protein with concurrent sup-
plementation of a slightly modiﬁed wild-type protein that
resists the RNAi treatment. In a proof-of-principle study
designed to test the feasibility of this approach, researchers
were able to speciﬁcally knockdown mouse rhodopsin
expression (in cultured retinal explants) using short hairpin
RNAs and concomitantly express the wild-type opsin (at
90% of native levels) with silent mutations in the shRNA
recognition sequence (Kiang et al., 2005). It remains to be
seen whether this strategy is applicable in an in vivo setting,
but it represents an exciting approach to rescue diseases
associated with gain-of-function mutations.
In spite of the use of improved viral vectors in these
cases, rescue tends to be partial and of limited duration.
Attempts to rescue retinal degenerations associated with
structural proteins in the photoreceptors have had even less
success. Ali’s group reported that AAV-mediated delivery
of peripherin 2 cDNA to the retinal degeneration slow
(Rds/) mutant mouse (null for peripherin 2/Rds) resulted
in a transduction rate of only 10% (Sarra et al., 2001).
Although the formation of outer segments was induced
and moderate improvement in photoreceptor function
was achieved, there was no signiﬁcant attenuation of the
severe photoreceptor cell loss seen in this model (Bain-
bridge, Tan, & Ali, 2006; Sarra et al., 2001).
While these encouraging reports suggest that AAV-med-
iated treatments may be clinically useful, the viral
approach still suﬀers from a number of physical limitations
including random integration into the host’s genome,
immunogenicity of the vector, and limitations in the insert
size (for rAAV, commonly reported as 4.7 kb (Flotte,
2000)). More importantly, there can be signiﬁcant toxic
side eﬀects such as stimulation of an immune response,
inﬂammation and neutralizing antibodies associated with
repeat treatment, and other potentially serious toxic out-
comes including death (Davis & Cooper, 2007; Jackson,
Juranek, & Lipps, 2006; Thomas, Ehrhardt, & Kay,
2003). Additionally, literature concerning the use of the
most common AAV vectors for direct gene delivery is con-
tradictory on both issues of transduction eﬃciency and
inﬂammatory response and on the duration and reproduc-
ibility of transgene expression. The lack of a clearly supe-
rior viral candidate for future clinical application of gene
therapy in the eye combined with the limitations of viral
gene therapy mentioned above make the development of
an eﬃcacious non-viral vector for the eye of supreme
importance.
There are several non-viral methods (Andrieu-Soler
et al., 2006) that have been suﬃciently successful in deliver-
ing genes into many tissues and have potentials for clinicaltrials. These include liposomes, DNA nanoparticles (Davis
& Cooper, 2007), or combination of both (Hayes et al.,
2006). Although liposomes are promising, they have shown
low transfection eﬃciency and can cause signiﬁcant inﬂam-
matory toxicity (Davis & Cooper, 2007). Alternatively,
compacted DNA nanoparticles have proved to be a very
useful vehicle for gene therapy and meet the majority of
the requirements discussed above for a successful vector.
Although there are many diﬀerent formulations of nano-
particles, they typically contain a segment of DNA or
RNA (circular or linear) which is compacted with a poly-
cationic polymer. Their size is quite small with a typical
range of 10–100 nm in diameter (Bondi et al., 2007; Coo-
per, 2007; Davis & Cooper, 2007; Farjo, Skaggs, Quiam-
bao, Cooper, & Naash, 2006; Fink et al., 2006; Hayes
et al., 2006; Konstan et al., 2004; Lee et al., 2007; Liu
et al., 2003; Zhang et al., 2007b; Ziady et al., 2003). These
small particles are taken up at the cell surface and traf-
ﬁcked to the nucleus within a short period of time. Delivery
of compacted DNA nanoparticles to the target yields med-
ium to high transfection eﬃciency; in many cases expres-
sion levels are several folds greater than those observed
after treatment with naked plasmid DNA. In one instance
the expression level was 200-fold higher than treatment
with the naked plasmid (Ziady et al., 2003). These results
are dependent on speciﬁcs of the nanoparticle formulation,
size, or electric charge (Bondi et al., 2007; Cooper, 2007;
Davis & Cooper, 2007; Fink et al., 2006; Harush-Frenkel,
Debotton, Benita, & Altschuler, 2007; Liu et al., 2003;
Walsh et al., 2006). Excellent preliminary studies have been
undertaken with polylactic acid and polylactide co-glyco-
lide nanoparticles in the retina, but so far they have not
been used for gene transfer to the mammalian retina (Bej-
jani et al., 2005; Bourges et al., 2003). Compacted polyeth-
ylene glycol (PEG) nanoparticles have been used to
eﬃciently transfect post-mitotic cells in vitro and in vivo
(Cooper, 2007; Davis & Cooper, 2007; Farjo et al., 2006;
Fink et al., 2006; Lee et al., 2007; Liu et al., 2003; Yurek,
Fletcher-Turner, & Cooper, 2005; Ziady et al., 2003). Addi-
tionally, these nanoparticles can be stably stored under a
variety of conditions and concentrations (up to 12 mg/ml
of DNA); they are tolerant of a wide range of tempera-
tures, salt concentrations and pH; and they tend to protect
their DNA or RNA from DNase or RNase degradation
(Bondi et al., 2007; Cooper, 2007; Davis & Cooper, 2007;
Farjo et al., 2006; Fink et al., 2006; Guo, 2005; Hayes
et al., 2006; Lee et al., 2007; Liu et al., 2003; Sesenoglu-
Laird et al., 2007). One of the most exciting features of
compacted DNA/RNA nanoparticles is their insert capac-
ity; some DNA-compacted nanoparticles can contain plas-
mids up to 20 kb and retain full functional competence
following in vivo administration (Fink et al., 2006). Studies
in humans and mice showed little to no toxicity in the tar-
geted tissues, and modest immune response when high con-
centration of the nanoparticles is used (Cooper, 2007;
Farjo et al., 2006; Konstan et al., 2004). The lack of serious
side eﬀects after treatment indicates that repetitive admin-
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another advantage over some viral vectors (Bourges
et al., 2003; Cooper, 2007; Davis & Cooper, 2007).
Recently, nanoparticles have had some success in phase
I/II clinical trials designed to treat cystic ﬁbrosis. The
nanoparticles used for those studies were compacted with
a lysine 30-mer linked to 10 kDa polyethylene glycol
(PEG) and contained CMV-CFTR cDNA. The success
of this trial highlights the clinical utility of this new tech-
nology as an eﬀective gene delivery vector in vivo (Konstan
et al., 2004). DNA nanoparticles can also be used to deliver
RNA (for RNA interference) to the diseased tissues to help
treat dominant genetic diseases. RNA nanoparticles have
been used to suppress malignant growth by inducing apop-
tosis in human lung cancer cells (Guo, 2005; Li & Huang,
2006). In spite of these successes, there are still barriers to
the universal application of this technology for the treat-
ment of human diseases. The biggest problem so far has
been the low transfection eﬃciency seen with some particles
and the short duration of gene expression which is typically
associated with most non-viral gene therapies.
In an eﬀort to develop such a non-viral strategy, our lab
has been cooperating with Copernicus Therapeutics, Inc.,
to optimize an exciting type of compacted-DNA nanopar-
ticle for use in the treatment of genetic retinal degenera-
tions. These nanoparticles are comprised of 30-mer lysine
polymers substituted with 10 kDa PEG and can be used
to compact any type of nucleic acid. One of the unique fea-
tures of these particles that contribute to their very small
size (8–20 nm in diameter) is that each particle contains
only one molecule of DNA. Various shapes of nanoparti-
cles can be achieved by varying the polylysine counterion
present at the time of compaction (Cooper, 2007; Fink
et al., 2006; Guo, 2005; Liu et al., 2003). This formulation
option helps facilitate the development of customized
nanoparticles for use in diﬀerent cell types (Farjo et al.,
2006; Fink et al., 2006; Kowalczyk et al., 2001; Liu et al.,
2003; Ziady et al., 2003). The particles are rod-like or ellip-
soidal in shape when compacted in the presence of either
acetate (AC) or triﬂuoroacetate (TFA) counterions, respec-
tively. The AC (or TFA)-CK30-PEG DNA nanoparticles
have been demonstrated to be non-immunogenic, non-
inﬂammatory, and non-toxic in various tissues. They
robustly transfect various non-dividing tissues in vivo with
eﬃciencies comparable to and up to 10-fold higher than
any viral vector: 30–80% of lung cells and >95% of retinal
cells were transfected. Furthermore, transfection eﬃciency
in brain tissues was comparable to those seen with viral
vectors (Cooper, 2007).
We have delivered these nanoparticles (containing
CMV-EGFP DNA and compacted with either AC or
TFA) to ocular tissues of adult wild-type mice by intravi-
treal or subretinal injection (Farjo et al., 2006). Two days
post injection, the injected eyes were harvested and GFP
expression levels were analyzed by qRT-PCR and immuno-
histochemistry. The results demonstrated that these nano-
particles can be targeted to diﬀerent tissues within the eyeby varying the injection site. Almost all cell types of the
eye were transfected by the nanoparticles and demon-
strated robust and dose-dependent levels of transgene
expression. Intravitreal injections drove strong GFP
expression in the inner retina (in the ganglion cell and inner
plexiform layers) and in other more anterior ocular tissues,
e.g. in cornea, trabecular meshwork, and lens. Conversely,
subretinal injection drove strong GFP expression in the
outer nuclear layer and retinal pigment epithelium as well
as in the optic nerve of the eyes. Nanoparticle uptake
was not limited to the site of injection and there was no evi-
dence of cellular inﬁltration or inﬂammation. These data
strongly suggest that compacted-DNA nanoparticles are
suitable for application to multiple types of ocular diseases.
Since intravitreal injection targets the tissue in the front of
the eye, this mode of therapy could be widely used for cor-
neal disease treatment while subretinal injection could be
used for diseases of the optic nerve and the retina. This sys-
tem provides tremendous promise for developing gene ther-
apy strategies to treat various ocular diseases (Farjo et al.,
2006).
One of the traditional limitations of non-viral vectors
has been passage of the vector across two physiological
barriers: the cell membrane and the nuclear membrane.
The most commonly accepted pathway for nanoparticle
internalization into the cytosol is endocytosis (Walsh
et al., 2006; Zhang et al., 2007a). Endocytosis can be
divided into two categories, phagocytosis (which requires
specialized cells) or pinocytosis. The latter pathway can
be subdivided into macropinocytosis (molecules
>120 nm), caveolin-mediated endocytosis (molecules
60 nm) and clathrin-mediated endocytosis (120 nm)
(Conner & Schmid, 2003). Positively charged nanoparticles
are known to use the clathrin-mediated endocytosis (Har-
ush-Frenkel et al., 2007). It was shown that C1K30-PEG
(a similar formulation to that used by Liu et al., 2003)
did not colocalize with markers of clathrin-coated endo-
somes (transferrin receptor), or late endosomes/lysosomes
(lysobisphosphatidic acid) (Walsh et al., 2006). Further-
more, nanoparticle entry into the cell was not blocked by
the presence of the inhibitors of clathrin or caveolae-med-
iated uptake, chlorpromazine and ﬁlipin III, respectively,
but was inhibited by amiloride (an inhibitor of the Na+/
H+ exchange required for macropinocytosis) suggesting
that C1K30-PEG nanoparticles enter cells via a diﬀerent
pathway than previously described for poly-L-lysine com-
pacted vectors (Walsh et al., 2006). The high transfection
eﬃciency we (and others) have observed with these nano-
particles suggests that they are adept at crossing the nuclear
membrane. It has been reported that the CK30PEG10k
nanoparticles are less than 24–25 nm in diameter which
would permit eﬃcient nuclear uptake across the 25 nm
nuclear membrane pores (Davis & Cooper, 2007; Liu
et al., 2003). This hypothesis is supported by the observa-
tion that transfection was inhibited in the presence of
wheat germ agglutinin (WGA), which blocks the nuclear
membrane pore (Davis & Cooper, 2007; Liu et al., 2003).
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25 nm have shown eﬃcient nuclear uptake which led inves-
tigators to further study nanoparticle traﬃcking. To iden-
tify the exact uptake mechanism used by our compacted-
DNA nanoparticles, the plasmid DNA was labeled with
rhodamine prior to compaction and tracked the particles
over time (Chen & Davis, 2007). Based on immunolocaliza-
tion and biochemical studies, these nanoparticles colocal-
ized with a nuclear/plasma membrane protein called
nucleolin. Cotransport of the nanoparticles and nucleolin
was traced at diﬀerent time points in Hela cells; after the
nanoparticles were transported through the cell membrane
into the cytoplasm they were then traﬃcked to the nucleus
by a nucleolin-mediated pathway (Chen & Davis, 2006;
Chen & Davis, 2007; Cooper, 2007). Cellular uptake and
nuclear localization is independent of the DNA plasmid
payload and gene transfer in cells can be eﬃciently blocked
by excess puriﬁed nucleolin protein added to the media
(Chen & Davis, 2006). DNA nanoparticles bind to nucleo-
lin with nanomolar aﬃnities (Chen & Davis, 2006). These
results clearly showed that cells that express nucleolin on
the cell surface can take up the DNA nanoparticles. Fur-
thermore, it is possible to retarget these DNA nanoparti-
cles to other tissues, such as liver, by adding cell-speciﬁc
ligands to the nanoparticles (Sun et al., 2007).
An additional limitation of non-viral vectors has been
short duration of expression. Although our compacted-
DNA nanoparticles exhibit high transfection eﬃciency, ini-
tial studies employing the CMV immediate-early promoter
indicated that expression was temporary (two weeks) (Far-
jo et al., 2006). This short duration was likely due to silenc-
ing of the CMV promoter (Bauer, Maier, Neyses, & Maass,
2005), (Chen, He, Meuse, & Kay, 2004), and attempts to
maximize duration of gene expression are critical. In order
to achieve long term tissue-speciﬁc transgene expression
in vivo, many modiﬁcations to the nanoparticles have been
performed. These include surface modiﬁcation of the nano-
particles with various coatings and targeting ligands (Li &
Huang, 2006; Li et al., 2007; Zhang et al., 2007b) and the
use of tissue speciﬁc or strong promoters as well as a vari-
ety of prokaryotic backbone elements. Recently, an idea
was proposed suggesting the incorporation of some fea-
tures of native chromosomes into the design of extrachro-
mosomal gene expression vectors can improve transgene
expression. These modiﬁcations are based on the knowl-
edge of the genome of the animal species in question, with
particular reference to the histone code, transcription fac-
tors and the transcriptional machinery, nuclear organiza-
tion, and structure of the nucleoskeleton and nuclear
matrix (Jackson, Juranek, &, Lipps, 2006). When a plasmid
containing a scaﬀold/matrix attachment region (S/MAR)
element combined with the alpha-1 antitrypsin promoter
(AAT) and the luciferase gene was hydrodynamically deliv-
ered to the mouse liver, 70% of cells were transfected and
gene expression was sustained for 6 months (a signiﬁcant
improvement over traditional plasmids) (Jackson et al.,
2006). This S/MAR sequence also protects the promoterfrom methylation and subsequent silencing of the trans-
gene (Argyros et al., 2007).
An alternate approach to increasing the duration of gene
expression was taken by Chen et al. who reported that mini-
circle plasmids in which all bacterial sequences were elimi-
nated (including the bacterial origin of replication and the
antibiotic resistance gene) promoted gene expression that
persisted for several years in the liver (Chen, He, Ehrhardt,
&Kay, 2003; Chen, He, &Kay, 2005). Our group is working
on implementing some of these exciting ideas in conjunction
with the compacted DNA nanoparticles to optimize gene
expression in the eye. We are utilizing linearized DNAs,
minicircle DNAs, and plasmids containing S/MAR regions
in our nanoparticles in an attempt to increase the duration
and levels of transgene expression. Our group’s most recent
studies have used compactedDNA nanoparticles to transfer
the normalmouse peripherin 2 (NMP), a product of theRDS
gene, under the control of tissue speciﬁc promoters to theRds
heterozygous retina, a mouse model of autosomal dominant
retinitis pigmentosa (ADRP). We have demonstrated that
transfection eﬃciency is above 90% and have achieved par-
tial structural and functional rescue (Cai, Fliesler, Cooper,
& Naash, 2007). Interestingly, both in this case and in some
other studies done in the lung, transgene expression was sus-
tained for several months suggesting that additional vector
modiﬁcations may not be necessary in all cases (Cai et al.,
2007).
In summary, compacted-DNA nanoparticle mediated
gene therapy provides a safe, eﬀective and promising sys-
tem for the delivery of therapeutic genes to target tissues
in the eye. They drive very speciﬁc and high levels of gene
expression and the expression can be sustained for several
months. The safe use of compacted DNA nanoparticles
in the clinical setting speaks to their viability as a potential
treatment strategy for human conditions (Konstan et al.,
2004). The use of this system in the treatment of genetic
diseases of the eye promises to be a strong alternative to
the existing collection of viral vectors.
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